Based on our forecasts, a long-term increase is expected, the "EARS" stock price prognosis for 2026-09-16 is 3.124 USD. With a 5-year investment, the revenue is expected to be around +30.73%. Your current $100 investment may be up to $130.73 in 2027.
Is EAR stock a buy?
Is Eargo a buy right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eargo in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Eargo stock.
Is EAR a good buy?
Valuation metrics show that Eargo, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of EAR, demonstrate its potential to underperform the market.
Is Eargo a good stock?
Is Eargo overvalued? According to Wall Street analysts Eargo's price is currently Overvalued.
Is EAR a buy?
Out of 3 analysts, 0 (0%) are recommending EAR as a Strong Buy, 0 (0%) are recommending EAR as a Buy, 2 (66.67%) are recommending EAR as a Hold, 0 (0%) are recommending EAR as a Sell, and 1 (33.33%) are recommending EAR as a Strong Sell. What is EAR's earnings growth forecast for 2022-2023?
Will SE stock go up?
Will Sea stock price grow / rise / go up? Yes. The SE stock price can go up from 155.630 USD to 262.804 USD in one year.
Is Eargo a good investment?
Eargo, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of EAR, demonstrate its potential to underperform the market.
Will Eargo stock go up?
Stock Price Forecast The 2 analysts offering 12-month price forecasts for Eargo Inc have a median target of 9.40, with a high estimate of 10.00 and a low estimate of 8.80. The median estimate represents a +106.14% increase from the last price of 4.56.
Is Stellantis a good stock to buy?
Stellantis has received a consensus rating of Buy.
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cytosorbents stock.